- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05888233
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension (RESIST)
Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension
Study Overview
Status
Intervention / Treatment
Detailed Description
Hypertension among African American adults in the United States has one of the highest prevalence rates in the world and is related to adverse changes in left ventricular (LV) structure and function. Hypertension is an underlying factor in greater than 50% of African American adults with heart failure and is the strongest risk factor in that population. African American adults have a 50% increased incidence of heart failure, due in large part due to the greater prevalence and severity of hypertension.
Heart failure occurs 8 years earlier in African American adults compared with Caucasians. Further, African American adults with heart failure have worse quality of life and depressive symptoms and have a 5-year mortality rate that is 34% higher than in Caucasians. Although African American adults have the highest death rate for heart failure, they are consistently under-represented in clinical trials. The greater heart failure burden among African Americans calls for further work to discover effective preventive and therapeutic strategies for this higher-risk population with heart failure preserved ejection fraction (HFpEF).
An estimated 10-20% of hypertensive patients have resistant hypertension (RHTN), defined as having controlled or uncontrolled blood pressure with the use of 3 or more medications that includes a diuretic. A recent study reported increased plasma xanthine oxidase (XO) activity and mitochondrial DNA damage associated molecular products (mtDAMPs) levels in African American adults with RHTN, compared with Caucasian adults with RHTN. This supports the consensus that oxidative stress is higher in African American adults. Increased xanthine oxidase in heart muscle cells causes a breakdown of muscle structure and a decrease in calcium sensitivity, resulting in left ventricular (LV) dysfunction. A recent study shows that diastolic blood pressure, and other indices of LV diastolic function positively relate to xanthine oxidase activity among African American but not Caucasian RHTN patients.
Given the higher level of xanthine oxidase activity and mtDAMPs in African Americans, the purpose of this clinical trial is to test whether blockade with Allopurinol (for 8 weeks) will improve LV diastolic function, exercise capacity and quality of life metrics in 50 African American Veterans with resistant hypertension.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Louis J Dellitalia, MD
- Phone Number: 4729 (205) 933-8101
- Email: Louis.Dellitalia@va.gov
Study Contact Backup
- Name: Betty M Pat, PhD
- Phone Number: (205) 612-7339
- Email: Betty.Pat@va.gov
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233-1927
- Recruiting
- Birmingham VA Medical Center, Birmingham, AL
-
Contact:
- Louis J Dellitalia, MD
- Phone Number: 4729 205-933-8101
- Email: Louis.Dellitalia@va.gov
-
Principal Investigator:
- Louis J Dellitalia, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Veteran
- African American
- Resistant hypertension diagnosis (defined as blood pressure greater than 140/90 mmHg at 2 clinic visits despite the use of 3 antihypertensive medications at pharmacologically effective doses)
- Locale - Birmingham, AL and surrounding areas
Exclusion Criteria:
- History of heart failure
- Chronic kidney disease (estimated creatinine clearance < 60 ml/min)
- Chronic steroid therapy
- Known coronary artery disease
- Known causes of secondary hypertension
- Already taking Allopurinol
Magnetic Resonance Imaging Exclusion
- Claustrophobia
- Cardiac implantable electronic device (permanent pacemaker and/or intracardiac defibrillator)
- Metal clips and/devices or other item that specifically prohibit safe CMR
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allopurinol - African American Veterans
Subjects will receive Allopurinol (300mg/daily) for 4 weeks.
If tolerated, dose will be increased to 600mg/daily for an additional 4 weeks.
Subjects will take Allopurinol (300-600mg/daily) for 8 weeks total
|
Single arm of Allopurinol treatment for 300mg/daily for 4 weeks then increased to 600mg/daily for an additional 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Normalized peak early diastolic filling rate (E)
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: Normalized peak early diastolic filling rate (E) after 8-weeks of treatment with Allopurinol.
(Range 1.5 - 3.0 EDV/sec)
|
8 weeks
|
Six minute walk test
Time Frame: 8 weeks
|
Change in exercise capacity by six minute walk test after 8-weeks of Allopurinol.
Timed activity for distance walked (Distance range approximately 400-800m; Further distance = better outcome)
|
8 weeks
|
Self Reported health survey for Heart Failure
Time Frame: 8 weeks
|
Change in self reported quality of life measures using Kansas City Heart Failure Questionnaire (KCCQ-12) after 8-weeks of Allopurinol.
Scale (Minimum - 0 ; Maximum - 100; High score = worse outcome)
|
8 weeks
|
Self reported Health Survey
Time Frame: 8 weeks
|
Change in self reported quality of life measures using the Quality of Life Medical Outcomes Study Questionnaire (SF 36 QOL) after 8-weeks of Allopurinol.
Scale (Minimum - 0; Maximum - 100; High score = worse outcome)
|
8 weeks
|
Left ventricular end-diastolic volume index
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: left ventricular end diastolic volume normalized to body surface area after 8-weeks of treatment with Allopurinol.
(Range 40 - 100 mL/m2)
|
8 weeks
|
LV end-diastolic mass index
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: LV end-diastolic mass indexed to body surface area after 8-weeks of treatment with Allopurinol.
(Range: 40-100 grams/m2)
|
8 weeks
|
LV end-diastolic fractional shortening
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: LV end-diastolic fractional shortening after 8-weeks of treatment with Allopurinol.
(Range: 15-80%)
|
8 weeks
|
LV end-diastolic mid-wall radius to wall thickness ratio
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: LV end-diastolic mid-wall radius to wall thickness ratio.
Ratio (no units; Range: 1.5-4.0).
|
8 weeks
|
Normalized peak late diastolic filling rate (A), EDV/s
Time Frame: 8 weeks
|
Change from baseline in left ventricular diastolic function index: Normalized peak late diastolic filling rate (A) after 8-weeks of treatment with Allopurinol.
(Range 1.3 - 4.5 EDV/sec)
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic Blood Pressure
Time Frame: 8 weeks
|
Change in systolic blood pressure after 8 weeks of Allopurinol.
Range: 120-200 mmHg
|
8 weeks
|
Xanthine Oxidase
Time Frame: 8 weeks
|
Change in systemic levels of xanthine oxidase (range - Xanthine oxidase activity, U/mg protein - Range 0 - 0.1)
|
8 weeks
|
mitochondrial DNA damage-associated molecular patterns
Time Frame: 8 weeks
|
Change in systemic levels of mitochondrial DNA damage-associated molecular patterns (range 0-5000 copies/uL)
|
8 weeks
|
Brain Natriuretic Peptide
Time Frame: 8 weeks
|
Change in systemic levels of brain natriuretic peptide (BNP) after 8 weeks of Allopurinol (Scale 0 to > 100 pgmL; Minimum 0; Maximum >100).
|
8 weeks
|
Diastolic Blood Pressure
Time Frame: 8 weeks
|
Change in diastolic blood pressure after 8 weeks of Allopurinol.
Range: 70-110 mmHg
|
8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Louis J Dellitalia, MD, Birmingham VA Medical Center, Birmingham, AL
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Heart Failure
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Gout Suppressants
- Allopurinol
Other Study ID Numbers
- F4655-P
- I21RX004655-01 (U.S. NIH Grant/Contract: Veterans Affairs)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Resistant Hypertension
-
National Institute of Cardiology, Laranjeiras,...CompletedArterial Hypertension | Resistant Arterial HypertensionBrazil
-
AstraZenecaNot yet recruitingResistant Hypertension | Uncontrolled HypertensionVietnam, Korea, Republic of, Philippines, China, Hong Kong, Turkey, Japan, India, Russian Federation, Argentina
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more
-
University Hospital, GenevaCompletedHypertension | Essential Hypertension | Resistant HypertensionSwitzerland
-
Yonsei UniversityRecruitingResistant HypertensionKorea, Republic of
-
ReCor Medical, Inc.CompletedResistant HypertensionGermany, Sweden, Netherlands
-
First Affiliated Hospital of Chengdu Medical CollegeNot yet recruitingResistant Hypertension
-
DeepQure Inc.RecruitingResistant HypertensionKorea, Republic of
-
Novartis PharmaceuticalsRecruitingResistant HypertensionChina, Italy, Spain, France, Netherlands, Taiwan, Germany, Czechia, Australia, Japan, United States, Bulgaria, United Kingdom, Poland, Austria, Slovakia
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
Clinical Trials on Allopurinol
-
Ardea Biosciences, Inc.Completed
-
Urica Therapeutics Inc.RecruitingHyperuricemia | GoutUnited States
-
Ardea Biosciences, Inc.Quotient ClinicalCompleted
-
AstraZenecaParexelCompletedChronic Kidney DiseaseGermany
-
Universita di VeronaCompletedChronic Heart FailureItaly
-
Ardea Biosciences, Inc.Completed
-
University of DundeeCompleted
-
Ardea Biosciences, Inc.Completed
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Failure | Elevated Serum Uric AcidUnited States, Canada